Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

RGene Therapeutics

1994 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$20M LATEST DEAL AMOUNT
Description

Developer of gene therapy and other nucleic acid-based drugs. The company intends to develop and commercialize gene therapies for in-vivo approaches to ovarian and breast cancer, an ex-vivo anti-sense treatment for chronic myelogenous leukemia and other applications of its gene and nucleic acid delivery systems.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Acquirer
AmpliPhi Biosciences
Primary Office
  • 2170 Buckthorne Place
  • Spring, TX 77380
  • United States

+1 (713) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore RGene Therapeutics’s full profile, request a free trial.

RGene Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 16-Apr-1996 $20M 0000 Completed
1. Early Stage VC Completed
To view this company’s complete deal history including valuation and funding, request access »

RGene Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Yellowstone Capital Partners PE/Buyout Minority 000 0000 000000 0

RGene Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Leaf Huang Ph.D Founder

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »